Status: Recruiting
Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts
This is a Phase I dose-escalation study to evaluate the safety of norovirus -specific T-cell (NST) therapy for chronic norovirus infection in participants following hematopoietic stem cell transplantation (HSCT) or who are immunocompromised due to PID and have not undergone HSCT, or Solid Organ Transplant (SOT) recipients.
Participants needed: 48
Trial details
Phase: Phase 1Age: 3-80Biological sex: AllType: InterventionalSponsor: Children's National Research InstituteUpdated: Jan 26, 2026Locations: 3
Eligibility criteria
Recipient of prior myeloablative or non-myeloablative allogeneic hematopoietic s... [+29]
Participants receiving biological or immunosuppressive monoclonal antibodies tar... [+17]